Preventing Alzheimer's disease progression


AZTherapies, Inc., is a privately held biotechnology drug development company founded in 2011 and headquartered in Boston, Massachusetts. AZTherapies is innovating the discovery, development and commercialization of a combination drug regimen for Alzheimer’s disease.  Alzheimer’s disease has no cure or viable commercial or clinical treatment option, and patients continue to rely on inadequate therapies.  The disease affects 35 million adults with symptoms of mental debilitation, memory loss and confusion to the point of incoherence all resulting in the inability to care for oneself.  Developing Alzheimer’s disease therapeutics that will fundamentally alter patient treatment, quality of life and disease management is a much needed area of focus, and AZTherapies has developed a clinical development program to target the disease at its earliest point of interception and before manifestation of disease symptoms.  

Our Programs

ALZT-OP pipeline

Easily administered small molecule drugs to prevent Alzheimer's progression and pathogenesis.


Eliminating missed and improper dosage for Alzheimer's patients.